GPP
Great Point Partners Portfolio holdings
AUM
$154M
1-Year Return
2.36%
This Quarter Return
+0.45%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$413M
AUM Growth
-$34.1M
(-7.6%)
Cap. Flow
-$21.5M
Cap. Flow
% of AUM
-5.19%
Top 10 Holdings %
Top 10 Hldgs %
59.29%
Holding
41
New
5
Increased
13
Reduced
6
Closed
11
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$24.1M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$16.9M |
| 3 |
BCYC
Bicycle Therapeutics
BCYC
|
$15.4M |
| 4 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
$14.9M |
| 5 |
Cytokinetics
CYTK
|
$11M |
Top Sells
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$49.3M |
| 2 |
BioAtla
BCAB
|
$17M |
| 3 |
MacroGenics
MGNX
|
$16.1M |
| 4 |
Sarepta Therapeutics
SRPT
|
$13.1M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
$10.9M |
Sector Composition
| 1 | Healthcare | 99.93% |
| 2 | Real Estate | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Dianthus Therapeutics
DNTH
$772M
| $3.39M | 0.82% |
73,125
| – | – |
|
|
CINC
27
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $1.4M | 0.34% |
+79,670
| New | +$1.4M |
|
28
Passage Bio
PASG
$22.6M
| $353K | 0.09% |
5,695
-70,210
| -92% | -$4.35M |
|
29
Rafael Holdings
RFL
$52M
| $304K | 0.07% |
122,694
-167,020
| -58% | -$414K |
|
|
30
Rocket Pharmaceuticals
RCKT
$347M
| – | – |
-500,526
| Closed | -$10.9M |
|
|
31
Sarepta Therapeutics
SRPT
$1.92B
| – | – |
-145,405
| Closed | -$13.1M |
|
32
Spyre Therapeutics
SYRE
$980M
| – | – |
-36,410
| Closed | -$4.32M |
|
|
ARNA
33
DELISTED
Arena Pharmaceuticals Inc
ARNA
| – | – |
-530,670
| Closed | -$49.3M |
|
34
Arbutus Biopharma
ABUS
$755M
| – | – |
-668,907
| Closed | -$2.6M |
|
|
35
BioAtla
BCAB
$27.7M
| – | – |
-864,300
| Closed | -$17M |
|
36
Cabaletta Bio
CABA
$140M
| – | – |
-472,433
| Closed | -$1.79M |
|
37
Dyne Therapeutics
DYN
$1.86B
| – | – |
-845,000
| Closed | -$10M |
|
|
38
MacroGenics
MGNX
$121M
| – | – |
-1,000,000
| Closed | -$16.1M |
|
39
Nektar Therapeutics
NKTR
$641M
| – | – |
0
| – | – |
|
40
ProQR Therapeutics
PRQR
$253M
| – | – |
-1,121,122
| Closed | -$8.98M |
|
41
Pyxis Oncology
PYXS
$93M
| – | – |
-400,000
| Closed | -$4.39M |
|